Jim Simons Alkermes Plc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Alkermes Plc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 5,810,160 shares of ALKS stock, worth $162 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

5,810,160

Previous 5,738,828 1.24%

Holding current value

$162 Million

Previous $189 Million 12.28%

% of portfolio

0.24%

Previous 0.3%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$26.59 - $32.65 $1.9 Million - $2.33 Million	71,332 Added 1.24%	5,810,160 $166 Million
Q1 2025 May 14, 2025	BUY	$28.08 - $36.0 $7.3 Million - $9.36 Million	260,100 Added 4.75%	5,738,828 $189 Million
Q4 2024 Feb 13, 2025	BUY	$25.7 - $31.46 $1.48 Million - $1.82 Million	57,697 Added 1.06%	5,478,728 $158 Million
Q3 2024 Nov 13, 2024	SELL	$23.01 - $28.55 $1.45 Million - $1.79 Million	-62,800 Reduced 1.15%	5,421,031 $152 Million
Q2 2024 Aug 09, 2024	SELL	$23.21 - $27.24 $9.36 Million - $11 Million	-403,320 Reduced 6.85%	5,483,831 $132 Million
Q1 2024 May 13, 2024	SELL	$26.4 - $32.56 $4.28 Million - $5.28 Million	-162,166 Reduced 2.68%	5,887,151 $159 Million
Q4 2023 Feb 13, 2024	SELL	$23.37 - $28.68 $1.56 Million - $1.91 Million	-66,696 Reduced 1.09%	6,049,317 $168 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $25.8 Million - $30.4 Million	949,600 Added 18.38%	6,116,013 $171 Million
Q2 2023 Aug 11, 2023	BUY	$28.34 - $33.63 $6.45 Million - $7.65 Million	227,500 Added 4.61%	5,166,413 $162 Million
Q1 2023 May 12, 2023	SELL	$25.31 - $29.02 $17.9 Million - $20.5 Million	-705,600 Reduced 12.5%	4,938,913 $139 Million
Q4 2022 Feb 13, 2023	BUY	$21.94 - $26.24 $1.94 Million - $2.32 Million	88,400 Added 1.59%	5,644,513 $147 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $5.14 Million - $7.44 Million	233,500 Added 4.39%	5,556,113 $124 Million
Q2 2022 Aug 12, 2022	BUY	$26.4 - $30.54 $12 Million - $13.9 Million	454,600 Added 9.34%	5,322,613 $159 Million
Q1 2022 May 13, 2022	BUY	$23.07 - $27.99 $1.32 Million - $1.6 Million	57,068 Added 1.19%	4,868,013 $128 Million
Q4 2021 Feb 11, 2022	BUY	$21.47 - $32.08 $1.43 Million - $2.13 Million	66,463 Added 1.4%	4,810,945 $112 Million
Q3 2021 Nov 12, 2021	SELL	$23.37 - $32.13 $12.5 Million - $17.2 Million	-534,131 Reduced 10.12%	4,744,482 $146 Million
Q2 2021 Aug 13, 2021	SELL	$18.78 - $25.15 $14.8 Million - $19.8 Million	-786,900 Reduced 12.97%	5,278,613 $129 Million
Q1 2021 May 13, 2021	SELL	$18.21 - $23.2 $16.2 Million - $20.6 Million	-889,900 Reduced 12.79%	6,065,513 $113 Million
Q4 2020 Feb 10, 2021	BUY	$15.39 - $22.1 $2.63 Million - $3.78 Million	171,200 Added 2.52%	6,955,413 $139 Million
Q3 2020 Nov 13, 2020	SELL	$16.16 - $20.66 $5.67 Million - $7.25 Million	-350,800 Reduced 4.92%	6,784,213 $112 Million
Q2 2020 Aug 13, 2020	SELL	$13.31 - $19.41 $613,591 - $894,801	-46,100 Reduced 0.64%	7,135,013 $138 Million
Q1 2020 May 14, 2020	BUY	$13.06 - $21.24 $7.11 Million - $11.6 Million	544,360 Added 8.2%	7,181,113 $104 Million
Q4 2019 Feb 13, 2020	BUY	$17.29 - $21.74 $30 Million - $37.7 Million	1,735,545 Added 35.41%	6,636,753 $135 Million
Q3 2019 Nov 13, 2019	BUY	$19.51 - $24.28 $18.5 Million - $23.1 Million	950,622 Added 24.06%	4,901,208 $95.6 Million
Q2 2019 Aug 12, 2019	BUY	$21.47 - $37.33 $49.4 Million - $86 Million	2,302,600 Added 139.72%	3,950,586 $89 Million
Q1 2019 May 14, 2019	BUY	$28.4 - $36.49 $24.2 Million - $31.1 Million	853,585 Added 107.45%	1,647,986 $60.1 Million
Q4 2018 Feb 13, 2019	BUY	$27.94 - $44.61 $22.2 Million - $35.4 Million	794,401 New	794,401 $23.4 Million

Others Institutions Holding ALKS

# of Institutions

395

Shares Held

176M

Call Options Held

558K

Put Options Held

427K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.58B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account